Ben Esque

Corstasis Therapeutics, Cardiology Enthusiast. Sunset Picture taker.

[Ben Esque @EsqueBen]

https://t.co/LT61LKM1dN

[Ben Esque @EsqueBen]

@PeterDiamandis Thank you Peter this is great

[Ben Esque @EsqueBen]

@PeterDiamandis As an owner who will work to leverage the free energy, robots and AI to help ensure the promise of abundance makes it those who may not have benefited from the early awareness proliferated by you and your network. Thank you for Moonshots

[Steve Greene @SJGreene_md]

#QuadTherapy for HFrEF

Essential, foundational, very large benefit....

But not enough to make #HFrEF a low-risk condition.
👇
https://t.co/P56nL6TvHZ

So where do additional therapies fit?
👇
https://t.co/4L2cNs0105

@gcfmd @JavedButler1

[Ben Esque @EsqueBen]

@elonmusk @Keller @farzyness #CYBERSUV!!

[Ben Esque @EsqueBen]

@cybertruck @ProxyPryor Cybersuv please

[Ben Esque @EsqueBen]

@elonmusk Totally! Exactly why I purchased @Tesla battery and solar…just wish it didn’t take 8 months to get it fixed🫤

[Ben Esque @EsqueBen]

Corstasis Therapeutics is pleased to announce that Enbumyst™
(bumetanide nasal spray) is now available for pre-order
through Carepoint Pharmacy and is now searchable on most Erx platforms.

Carepoint is now accepting e-prescriptions for Enbumyst and provides nationwide dispensing services.
For full ordering instructions — including EMR search
guidance, required prescription details, NDC, quantity
options, and optional prior authorization information —
access the step-by-step Carepoint Ordering Guide here:
👉https://t.co/PxVGWEoScD

Learn more about ENBUMYST, including potential risks, at https://t.co/oGPcyWyPij

#Biotech #SpecialtyPharmacy #HealthcareOperations
#CHF #homeiswheretheheartis
@bkolskk @EricAdler17 @FudimMarat @AHajduczok @Murmur_MD @dranulala @DrAmirKaki @AndrewPAmbrosy @NavinKapur4 @BurkhoffMd @aidanraneymd @jefftylermd @joewalshmd @Abraham_Jacob

[Ben Esque @EsqueBen]

Corstasis Therapeutics is pleased to announce that Enbumyst™
(bumetanide nasal spray) is now available for pre-order
through Carepoint Pharmacy and is now searchable on most Erx platforms.

Carepoint is now accepting e-prescriptions for Enbumyst and provides nationwide dispensing services.
For full ordering instructions — including EMR search
guidance, required prescription details, NDC, quantity
options, and optional prior authorization information —
access the step-by-step Carepoint Ordering Guide here:
👉https://t.co/PxVGWEoScD

Learn more about ENBUMYST, including potential risks, at https://t.co/oGPcyWyPij

#Biotech #SpecialtyPharmacy #HealthcareOperations
#CHF #homeiswheretheheartis
@bkolskk @EricAdler17 @FudimMarat @AHajduczok @Murmur_MD @dranulala @DrAmirKaki @AndrewPAmbrosy @NavinKapur4 @BurkhoffMd @aidanraneymd @jefftylermd @joewalshmd @Abraham_Jacob

[Alexander Hajduczok, MD 🇺🇦🙏 @AHajduczok]

Check out our new paper out in HF Reviews where we explore alternative pathways for treatment of acute decompensated HF, including emerging treatment strategies including intranasal bumetanide.

@AndrewJSauer @UCSDCardiology
@AndrewPAmbrosy

[Pablo Corral MD @drpablocorral]

🚨 AHA 2025 | CORALreef Lipids Trial

A true game changer in lipid management.

💊 Enliciditide (MK-0616) — the first oral PCSK9 inhibitor — achieved a 57% LDL-C reduction at week 24 and −50% sustained at week 52 vs placebo (p<0.001).

👥 Phase 3 trial, 2,912 patients with ASCVD or at high risk, across 14 countries, with excellent safety profile.

👉Takeaway: efficacy and safety comparable to injectable PCSK9 inhibitors — but in a once-daily oral tablet.

☝️A new era in PCSK9 inhibition and cardiovascular prevention.

@society_eas
#AHA2025

[Gregg Fonarow MD @gcfmd]

Heart failure incidence, cost increasing in US https://t.co/U4F6hAPuBt

@HFSA @JCardFail @GoHealio @DOM_UCLA @UCLAHealthNews

[Muthu Vaduganathan @mvaduganathan]

Most Updated Global Burden of Cardiovascular Disease now out in @JACCJournals

80% (!) of CV disease burden is attributable to modifiable RFs

Top modifiable risks in 2023:

⚠️ High systolic BP
⚠️ Dietary risks
⚠️ High LDL cholesterol
⚠️ Air pollution

🔗 https://t.co/EIvzZMQQPC

[Dhruv Kazi @kardiologykazi]

🚨 A new, practical framework for evaluating the economic value of cardiovascular drugs, devices, and preventive strategies
Just published in @JACCJournals and @CircAHA

Here’s what’s new, why it matters, and how it will shape care. 🧵

[Ben Esque @EsqueBen]

@cb_doge When Cybersuv thanks

[Anu Lala (Anuradha Lala-Trindade) @dranulala]

#WordsMatter @JCardFail #FunctionNotFailure @hfsa

[Anu Lala (Anuradha Lala-Trindade) @dranulala]

#HFSA2025 plenary &amp; open session now!! Celebrating 30 years!!!! @HFSA @JCardFail

Congratulations to award winners, outgoing president @DukeHFDoc, @NutritionHF for chairing ASM this year &amp; so many others!

[Eiran Gorodeski, MD, MPH @EiranGorodeski]

Bumetanide nasal spray, now FDA approved. One use cartridge. What’s the use case in your practice? #HFSA2025

[Anu Lala (Anuradha Lala-Trindade) @dranulala]

It’s #HFSA2025 time!
Celebrating 30 years of this amazing organization that brought so many of us together! @HFSA

Marvelous pre-mtg day w/@JCardFail team, packed Device Day &amp; seeing friends &amp; colleagues

Tomorrow 💜💜💜 for patients!!

[Andrew J Sauer MD @AndrewJSauer]

Presenting late-breaking VITAL-HF results Sunday at @HFSA : multicenter RCT (n=178, 7 US sites) of a remote, digital GDMT titration program vs usual care over 6 months. Primary: change in HFC score; key secondaries: KCMO, dose attainment, safety. #HFSA2025

https://t.co/jyw3y0BEvJ